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Abstract
Introduction and hypothesis We compared cure rates and
complication rates in patients who had undergone primary or
recurrent (secondary) surgery for stress urinary incontinence
(SUI).
Methods A retrospective cohort study that included patients
who underwent surgery to treat SUI in a tertiary referral center
was carried out. All patients had, predominantly, SUI. Exclu-
sion criteria were patients with a neurogenic bladder or a
neobladder and patients without postoperative follow-up
(FU). The primary objective was to assess the success rate,
defined as cured SUI or improved SUI at six weeks and at the
latest available moment of FU. The secondary objective was
to assess complications.
Results A total of 541 womenwith SUI underwent surgery for
SUI between 2002 and 2010. After exclusion of 102 patients a
total of 242 patients with primary SUI and 197 patients with
recurrent SUI were identified. The success rate at first FU was
89%. At last FU (median 205 days) the success rate was 83%
(P<0.01). There were no significant differences in success
rate between primary and recurrent surgery at first FU. The
overall success rate of primary surgery was 86%; for recurrent
surgery it was 79 %. During surgery, 27 bladder injuries oc-
curred (6.2 %), with no significant difference between the two
groups. At last FU, 11 patients (2.6 %) had persistent residual
volume, necessitating prolonged clean intermittent self-
catheterization.
Conclusions The results of recurrent surgery to treat re-
current or persistent SUI are still good in experienced
hands and do not significantly differ from results of
primary surgery. The complication rates are comparable
to those of primary surgery.
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Introduction
Stress urinary incontinence (SUI) is the complaint of involun-
tary loss of urine on physical exertion, or on sneezing or
coughing [1]. Nowadays, there are plenty of treatments for
SUI. The mid-urethral sling (MUS) is currently the gold stan-
dard treatment for SUI, with high success rates of approxi-
mately 77–85 % [2, 3].
Nonetheless, a subgroup of patients experience recurrent or
persistent SUI after treatment of their complaints and request
retreatment. An estimated 8–17 % of the women who have
undergone surgical therapy for urinary incontinence, are likely
to undergo a second surgical treatment within 8–10 years [4,
5].
There are several options for the management of recurrent
SUI, including repeating the previously performed procedure,
MUS, Burch colposuspension, and bulking agent injections
[6, 7]. Unfortunately, performing a recurrent procedure
attempting to solve SUI does not guarantee complete dryness.
To date, there have been limited data on the optimal ap-
proach to recurrent SUI, in particular for recurrent SUI after
more than two surgical procedures. The aim of this study was
to compare cure rates and complication rates in patients who
had undergone primary and recurrent surgery for SUI.
Materials and methods
Patient selection
We conducted a retrospective cohort study including all
medical records of the patients who underwent surgical
SUI treatment between January 2002 and March 2010
in the departments of gynecology and urology of the
Radboud University Medical Centre, a tertiary referral
center in the Netherlands.
Patient enrolment is shown in Fig. 1. A total of 541 patients
were identified. All patients had, predominantly, SUI. SUI
was defined as the complaint of involuntary loss of urine on
physical exertion, or on sneezing or coughing [1]. Exclusion
criteria were patients with predominantly overactive bladder
(OAB) symptoms (n=12), neurogenic bladder of various
causes (n=29), patients with a neobladder (n=2), patients
who had last undergone surgery elsewhere (n=19), and pa-
tients without postoperative follow-up (n=3). Patients who
had undergone a xenograft sling (n=37) were excluded be-
cause of the experimental setting of the surgery in a research
setting.
Every patient was added to our database only once, even if
the patient underwent surgery in our hospital more than once.
In recurrent cases, only the result of the last surgical procedure
was analyzed.
Study outcomes
The primary outcome of the study was the cure rate based on
findings during physical assessment and patient statements at
follow-up at six weeks and at the latest available follow-up.
Subjective cure/improvement was assessed by an open ques-
tion during clinical visits and a standardized questionnaire.
Objective cure/improvement was tested by a cough test with
a full bladder, voiding diary or micturition diary, and a
urodynamic investigation if indicated. SUI was considered
to have been cured when episodes of involuntary urine leak-
age during stressful activities according to the patient
remained absent and there was no demonstrable SUI during
physical examination. Improvement was defined as a signifi-
cant decrease in urine leakage without further treatment. Fail-
ure to cure SUI was classified as unchanged or deteriorated
leakage of urine. An unchanged condition was defined as
persistent SUI after surgery for SUI. If the urine leakage due
to SUI worsened according to the patient, this was classified
as deterioration.
Secondary outcomes included the number of peri-operative
and postoperative complications, including vaginal tape expo-
sure, pain, and longer term voiding dysfunction.
Surgical procedures, postoperative care, and follow-up
Possible surgical procedures were Burch colposuspension,
tension-free vaginal tape (TVT), transobturator tape (TOT),
minitape, and periurethral bulking agents.
Operative time and blood loss were measured in every
surgical procedure for SUI. Substantial blood loss was defined
as more than 500 ml.
If another tape had been placed previously, the tape placed
during the primary operation was not specifically identified or
removed if it was still in place and not hampering the second-
ary procedure. Intraoperative urethrocystoscopy was per-
formed during all TVT and minitape operations to ensure that
no damage had occurred to the urethra or bladder during the
procedure.
Among the patients who received a TVT, a TOT or a
minitape, a transurethral catheter (TUC) was inserted and kept
in position for at least one day.
When performing a Burch colposuspension, a suprapubic
catheter (SPC) was inserted in every patient during surgery
under direct visualization by intraoperative cystoscopy.
Voiding attempts were started one day postoperatively after
TVT, TOT, and minitape surgery, and two days postoperative-
ly after Burch colposuspension. If the patient was able to void
well and the postvoid residual volume was less than 100 ml on
two consecutive occasions, the SPC or TUCwas removed and
the patient was discharged. In the case of unsatisfactorily
voiding, clean intermittent self-catheterization (CISC) was
started or the patient was discharged with a TUC or SPC in
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situ and checked after seven days. If the patient was unable to
void well at that time, the catheter was kept in place for an-
other week or the patient started CISC and was regularly
checked in our hospital.
The periurethral bulking injections were given with local
anesthesia and injected into the submucosa through the ure-
thra under direct urethroscopic guidance. Three to four
deposits were placed at positions 0.5–1 cm distal to the blad-
der neck. Patients were discharged after successful voiding
without significant postvoid residual urine (less than 100 ml).
Patients were assessed at approximately six weeks
and three months postoperatively, and thereafter if nec-
essary. Median time between surgery and the last
follow-up was 205 days.
Patients who had any surgery for stress urinary
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Fig. 1 Patient enrolment
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The cure rate was assessed by the observation of involun-
tary leakage from the urethra synchronous with coughing and
also based on patient statements.
Statistical analysis
In accordance with Dutch law, retrospective observational
studies are exempt from submission for approval to a medical
ethics review committee. However, the principles of the Dec-
laration of Helsinki were followed. We used the Mann–Whit-
ney U test for independent variables without a normal distri-
bution and the Chi-squared test for categorical variables.
All statistical analyses were performed using SPSS soft-
ware for Windows (version 17.0; SPSS, Chicago, IL, USA),
with P values<0.05 considered statistically significant.
Results
Patient population
A total of 439 patients met the inclusion criteria, of whom 242
had had primary anti-incontinence surgery and 197 recurrent
surgery.
Of the 439 patients included, 40% (n=176) were treated by
gynecologists and 60 % (n=263) were treated by urologists.
Urologists treated 85 % (n=167) of the recurrent SUI cases.
Baseline characteristics
Patient characteristics are listed in Table 1. Patients with re-
current SUI symptoms had more frequent voiding difficulties
Table 1 Baseline characteristics
Complete cohort (N=439) Primary surgery group (n=242) Recurrent surgery group
(n=197)
P
Number Median [range] or
mean ± SD or number
(%)
Number Median [range] or
mean ± SD or number
(%)
Number Median [range] or
mean ± SD or number
(%)
Age at time of surgery, years 439 59 [22–94] 242 56 [38–94] 197 62 [22–92] <0.01*
Parity, number 361 2 [0–6] 217 2 [(0–6] 144 2 [0–6] 0.16*
Menopause and/or using HRT 388 250 (64.4) 213 115 (54.0) 175 135 77.1 <0.01**
BMI, kg/m2 426 27.2 ±5.0 235 26.7 ±4.8 191 27.9 ±5.1 0.03*
Smoking 421 84 (19.1) 231 46 (19.9) 190 38 (20.0) 0.98**
Current respiratory disease 439 81 (18.5) 242 41 (16.9) 197 40 (20.3) 0.37**
Surgical history
POP surgery
≥1 surgery for POP 439 94 (21.4) 242 34 (14.0) 197 60 (30.5) <0.01**
≥2 surgeries for POP 439 25 (5.7) 242 7 (2.9) 197 18 (9.1) 0.01**
SUI surgery
≥1 surgery for SUI 439 197 (44.9) 242 – – 197 197 (100.0) –
≥2 surgeries for SUI 439 97 (22.1) 242 – – 197 97 (49.2) –
≥3 surgeries for SUI 439 38 (8.7) 242 – – 197 38 (19.3) –
Hysterectomy 439 140 (31.9) 242 59 (24.4) 197 81 (41.1) <0.01**
AH and SVH 433 87 (20.1) 241 32 (13.3) 192 55 (28.6) <0.01**
VH 433 48 (11.1) 241 26 (10.8) 192 22 (11.5) 0.83**
MUI 437 190 (43.5) 241 99 (41.1) 196 91 (46.4) 0.26**
Micturition frequency
Daily frequency 393 8 [3–20] 217 8 [4–20] 176 8 [3–17] 0.84*
Nightly frequency 399 1 [0–6] 222 1 [0–5] 177 2 [0–6] 0.22*
Recurrent UTI 429 104 (24.2) 235 45 (19.1) 194 59 (30.4) <0.01**
Preoperative use of a CISC or TUC 439 19 (4.3) 242 3 (1.2) 197 16 (8.1) <0.01**
HRT hormone replacement therapy, BMI body mass index, SUI stress urinary incontinence, AH abdominal hysterectomy, SVH supravaginal hysterec-
tomy, VH vaginal hysterectomy, MUI mixed urinary incontinence, UTI urinary tract infection, CISC clean intermittent self-catheterization, TUC
transurethral catheter
*Calculated using the Mann–Whitney U test
**Calculated using the Chi-squared test
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and used TUC or performed CISC more frequently (1.2 % vs
8.1 %; P<0.01).
Peri-operative outcomes
Peri-operative data are listed in Table 2.
In 29 % of cases the incontinence surgery was combined
with other surgery, such as pelvic organ prolapse (POP) sur-
gery or removal of previous tapes. After the exclusion of con-
comitant surgeries, we found seven cases (5.2 %) of excessive
bleeding during recurrent procedures carried out to treat SUI
and 10 (5.7 %) during primary procedures.
One urethral lesion was observed in a patient with an in-
correct location of her previous TVT sling, which was re-
moved during the same surgery. The integrity of the urethra
was restored and the patient received long-term indwelling
catheterization.
All 27 (6.2 %) bladder injuries occurred during TVT sur-
gery; however, there was no significant difference between the
two groups. All bladder lesions were recognized intraopera-
tively by cystoscopy. If a bladder lesion was noticed, the sling
was removed, the trocar was replaced and the sling reinserted.
There was no prolonged hospital stay in these patients.
Postoperative outcomes
Postoperative data and long-term data are listed in Table 3.
Postoperative complications before discharge were hemato-
ma (n=4), subsequent bleeding (n=2), urinary tract infection
during hospital stay (n=8), and pain (n=22). Re-interventions
(n=4) were needed in cases of peri-operative bleeding (n=1),
postoperative bleeding (n=2), and retensioning of a TVT (n=
1). Postoperative pain was observed significantly more fre-
quently in patients who received concomitant surgery (68 %
vs 32 %; P<0.01) and did not occur significantly more often in
patients who underwent recurrent surgery (27 % vs 73 %; P=
0.09). Most reported postoperative complaints of pain were
located inguinally after TOT (n=11; 7 %) and suprapubically
after Burch colposuspension (n=7; 23 %). At first follow-up
(six weeks postoperatively), 64 % (n=14) of the 22 patients
with postoperative pain did not have pain anymore. At last
follow-up, 77 % (n=17) of the 22 patients with postoperative
pain no longer had pain.
Before discharge, 53 patients (12.6 %) were unable to void
properly or had post-void residual of more than 100 ml. Most
patients were able to void well after one week without
postvoid residual. Eleven patients (2.6 %) had persistent
Table 2 Peri-operative data and complications
Complete cohort (N=439) Primary surgery group (n=242) Recurrent surgery group (n=197) P
Number Median [p5–p95] or
number (%)
Number Median [p5–p95] or
number (%)
Number Median [p5–p95] or
number (%)
Concomitant surgery 439 129 (29.4) 242 67 (27.7) 197 62 (31.5) 0.39*
Operating time (skin to skin), mina 286 25 [9–49] 160 25 [11–47] 127 25 [6–50] 0.58**
Burch colposuspension 5 57 [50–65] 4 58 [50–65] 1 57 [57–57] 1.00**
Urethral bulking agents 43 11 [4–27] 9 12 [9–20] 34 10 [4–30] 0.45**
TVT 130 28 [19–50] 68 27 [18–46] 62 29 [18–53] 0.67**
TVT-O/TOT 103 22 [11–39] 74 22 [11–39] 29 28 [15–58] 0.03**
Minitape 5 22 [17–24] 4 23 [17–24] 1 20 [20–20] 0.47**
Blood loss (ml)a 265 50 [0–200] 145 50 [0–200] 120 50 [0–200] 0.08**
Burch colposuspension 4 150 [50–600] 3 150 [50–150] 1 600 [600–600] 0.16**
Urethral bulking agents 58 0 [0–0] 18 0 [0–0] 40 0 [0–0] 0.50**
(TVT) 106 50 [10–265] 54 50 [10–350] 52 50 [10–200] 0.04**
TVT-O/TOT 96 50 [10–215] 70 50 [10–145] 26 50 [10–365] 0.67**
Minitape 1 50 [50–50] 0 – – 1 50 [50–50] –***
Perioperative complications
Bladder lesion 439 27 (6.2) 242 11 (4.5) 197 16 (8.1) 0.12*
Urethral lesion 439 1 (0.25) 242 0 (0.0) 197 1 (0.5) –***
Blood loss>500 mla 310 17 (5.5) 175 10 (5.7) 135 7 (5.2) 0.84*
TVT transvaginal tape, TVT-O/TOT transobturator tape
*Calculated using the Chi-squared test
**Calculated with Mann–Whitney U test
***Not enough valid cases to calculate a P value
aWithout concomitant surgery
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retention, necessitating prolonged CISC or an indwelling cath-
eter. Two women wanted lysis of the tape, which was per-
formed. Also, three patients had an extended postoperative
transurethral catheter for special reasons (one urethral lesion
and two patients with voiding dysfunction after a bladder le-
sion), but could void normally afterwards.
Pre-operatively, 19 patients had a TUC or a SPC or per-
formed CISC. Directly after surgery four of these patients still
had urinary retention and needed to perform CISC. The other
15 patients were able to void spontaneously without
considerable residual volume, but ten of them needed a cath-
eter at last follow-up (205 days).
Long-term outcomes
The success rates of primary and recurrent surgery are com-
pared in Table 4.
Overall, 89 % of the patients had relief, either complete or
improved, of SUI symptoms at first follow-up. At last follow-
up the success rate was 83 %. There were no significant
Table 3 Postoperative data and long-term data
Complete cohort (N=439) Primary surgery group (n=242) Recurrent surgery group
(n=197)
P
Number Median [range] or
number (%)
Number Median [range] or
number (%)
Number Median [range] or
number (%)
Postoperative data
Pain a 439 22 (5.0) 22 16 (72.7) 22 6 (27.3) 0.09*
Pain b 310 7 (2.3) 175 3 (1.7) 135 4 (3.0) 0.47**
After Burch colposuspension 5 2 (40.0) 4 2 (50.0) 1 0 (0.0) 1.00**
After TVT 137 2 (1.5) 74 0 (0.0) 63 2 (3.2) 0.21**
After TOT 103 3 (2.9) 74 1 (1.4) 29 2 (6.9) 0.19**
Hematoma a 439 4 (0.9) 242 3 (1.2) 197 1 (0.5) 0.63**
Re-intervention due to complication a 439 4 (0.9) 242 3 (1.2) 197 1 (0.5) 0.63**
Urinary retention c 420 53 (12.6) 239 31 (13.0) 181 22 (12.2) 0.80*
Temporary 420 42 (10.0) 239 25 (10.5) 181 17 (9.4) 0.77*
Persistent 420 11 (2.6) 239 6 (2.5) 181 5 (2.8) 0.77*
Duration of urinary catheter (days) a 420 1 [0–34] 236 1 [0–9] 184 1 [0–34] 0.10***
Hospital stay (days) a 439 1 [0–15] 242 1 [0–10] 197 1 [0–15] <0.01***
Hospital stay (days) b 310 1 [0–15] 175 1 [0–8] 135 1 [0–15] 0.14***
Long-term data
Micturition frequency a
Daily frequency 191 8 [2–20] 105 8 [2–20] 86 8 [3–20] 0.31***
Nightly frequency 187 2 [0–7] 103 1 [0–7] 84 2 [0–5] 0.43***
De novo OAB symptoms a 243 52 (21.4) 139 24 (17.3) 104 28 (26.9) 0.07*
Pain a 431 57 (13.2) 236 38 (16.1) 195 19 (9.7) 0.05*
Pain b 308 32 (10.3) 174 21 (12.1) 134 11 (8.1) 0.27*
After TVT 136 16 (11.8) 74 9 (12.2) 62 7 (11.3) 0.87*
After TOT 102 11 (10.8) 73 8 (11.0) 29 3 (10.3) 0.93*
Vaginal exposure a 439 13 (3.0) 242 8 (3.3) 197 5 (2.5) 0.64*
After MUS 346 8 (2.3) 200 5 (2.5) 146 3 (2.1) 0.79**
After bulking agents 63 5 (7.9) 19 3 (15.8) 44 2 (4.5) 0.13**
*Calculated using the Chi-squared test
**Calculated using Fisher’s exact test
***Calculated using the Mann–Whitney U test
a Concomitant surgery included
b Concomitant surgery excluded
cNot including the patients who had pre-operative CIC, CAD or a suprapubic catheter (n=19)
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differences between primary and recurrent surgery at first-fol-
low-up, but at last follow-up the success rate of recurrent
surgery was lower (79 %) than the success rate of 86 % for
primary surgery at last follow-up (P=0.05).
Of the 100 patients in whom primary surgery failed, 68
patients had undergone primary surgery with a MUS previ-
ously. Most of them were treated with a new MUS (79 %, n=
54); the success rate was 85 %. Another 16 % (n=11) were
treated using periurethral bulking agents; the success rate was
73 %.
Twenty-three patients had undergone primary surgery
using periurethral bulking agents previously. Most of them
were treated with an MUS (78 %, n=18); the success rate
was 89%.Another 17% (n=4) were treated using periurethral
bulking agents; the success rate was 75 %.
At first follow-up, vaginal exposure was reported in five
patients (2.1 %) after primary surgery and in three patients
(1.5 %) after recurrent surgery (P=0.74).
Urethral mucosal exposure occurred twice after bulking
agents and six times after MUS.
At last follow-up, two of these patients had persistent ex-
posure in the vagina and needed re-excision of their MUS (n=
1) and bulking agents (n=1). Five other patients reported new
exposure at the last follow-up (three times after bulking agents
and twice after MUS), all patients underwent surgical
excision.
Discussion
This manuscript clearly illustrates that the success rates of
primary and secondary procedures are acceptable, with no
significantly higher rates of complications. In this study we
found success rates of 86 % for primary cases and 79 % for
recurrent cases. Overall, only 17 % of patients experienced no
relief of SUI symptoms six months after surgery.
In a recent review, Pradhan et al. noted a subjective cure
rate following MUS for recurrent SUI after any previous sur-
gery of 79% at follow-up of 30±29 months [8]. This cure rate
is slightly lower than our success rate of 84 % for surgery with
MUS at last follow-up, but other criteria for success were
applied in the various studies and the follow-up of our study
is much shorter.
We observed a lower cure rate with TOT (79 %) than with
the retropubic tape (86 %) for recurrent SUI. This is in line
with the results described in the review by Pradhan et al.,
although they reported lower success rates (54 %) than in this
study [8]. This could also have been caused by the relatively
low number of our patients who underwent TOT to treat re-
current SUI. These results contradict the results of the system-
atic review by Agur et al., who described TOT as having
similar patient-reported and objective cure/improvement rates
compared with retropubic TVT in the surgical treatment of
women with recurrent SUI [9].
In our study, treatment with bulking agents resulted more
often in improvement than in complete dryness (54% and 8%
respectively). In patients with recurrent SUI symptoms the
results with bulking agents were slightly higher (59 % and
9 % respectively). These low percentages are consistent with
those of a previous study, in which bulking agents after pre-
viousMUS showed a cure rate of 35% for a median follow-up
of 10 months [10]. However, patient satisfaction was relative-
ly high (77 %) in this study after this minimally invasive
procedure. This implies that bulking agents could play a role
Table 4 Success of primary surgery vs recurrent surgery for stress urinary incontinence
Success at first follow-up
(6 weeks)
P value primary surgery
compared with recurrent
surgery*






















30 21 (91.3) 4 (57.1) 0.07 20 (87.0) 4 (57.1) 0.12
Urethral bulking
agents
63 12 (63.2) 36 (81.8) 0.11 9 (47.4) 30 (68.2) 0.12
TVT 193 84 (92.3) 94 (92.2) 0.97 82 (90.1) 88 (86.3) 0.41
TVT-O/TOT 147 99 (94.3) 34 (81.0) 0.01 94 (89.5) 33 (78.6) 0.08
Minitape 6 4 (100.0) 2 (100.0) 1.00 4 (100.0) 1 (50.0) 0.33
Total 439 220 (90.9) 170 (86.3) 0.127 209 (86.4) 156 (79.2) 0.046
*Calculated using the Chi-squared test
Int Urogynecol J (2015) 26:997–1005 1003
in secondary treatment to improve SUI symptoms after a pre-
vious failed procedure, especially when more invasive proce-
dures are not an option.
As we performed only seven Burch colposuspensions in
patients with recurrent SUI symptoms, it is difficult to gener-
ate proper conclusions.
Stav et al. have argued that de novo OAB symptoms are
more common in patients who underwent a repeat MUS to
treat persistent or recurrent SUI [2]. In our study, de novo
OAB symptoms were seen in 52 (21 %) patients, with no
significant difference between the two groups.
According to a systematic review, the incidence of de novo
urgency after MUS to treat recurrent SUI is between 5.5 and
20 % [8]. A possible explanation for the higher incidence of
27 % (after any recurrent procedure) in our series is the high
number of patients who had undergone more than two previ-
ous operations to treat SUI. According to Pradhan et al., the
rate of urinary tract injuries is 8 % with retropubic sling pro-
cedures during repeat continence surgery, while it is 4 % dur-
ing primary retropubic sling procedures [8]. These results are
consistent with those we found in our study (8 % and 5 %
respectively).
As described above, we found seven cases of excessive
bleeding (2 %) during recurrent procedures carried out to treat
SUI. According to the literature, the incidence of excessive
bleeding during repeat SUI surgery is 2–7 % [8].
Postoperatively, 12 % of patients had symptoms of voiding
dysfunction after recurrent surgery. At last follow-up, 11 pa-
tients (3 %) had persistent residual volumes, necessitating
prolonged CISC. There was no significant difference between
the patients who underwent primary surgery and the patients
who underwent recurrent surgery. Pradhan et al. described the
frequency of voiding dysfunction after recurrent surgeries as
varying between 4 and 16 % [8].
In our study, success rates of urethral bulking agents and
TVT turned out to have significantly worsened by time of the
last follow-up visit compared with the first follow-up. Repeat
continence surgery is often difficult as a result of retropubic
scarring and adhesions with the distortion in anatomy from
previous surgeries, which may increase the risks of intraoper-
ative complications [11]. Amaye-Obu and Drutz found that
the first surgical approach for the management of SUI is the
best, because cure rates decline proportionately with the num-
ber of subsequent operations performed [12]. We also found
this trend in our data.
The impact of this study is limited by its retrospective de-
sign and descriptive nature. It is, therefore, susceptible to re-
call and interpretation bias. Moreover, since data were collect-
ed retrospectively, 30 % of the patients had a follow-up of less
than 3 months. Therefore, the postoperative follow-up may
have been too short to find recurrences of SUI in some cases.
The fact that our academic hospital is a tertiary care center
limits the generalizability of our conclusions. Some patients
needed multiple procedures to achieve optimal relief of their
SUI symptoms. In our study, nearly 9 % of the patients needed
three or more procedures, with a maximum of as many as
eight previous procedures (n=1).
Despite these limitations, this study is strengthened by the
large number of patients, by the fact that all operations were
performed in one center by experienced surgeons using the
same surgical techniques, and by the detailed data available
from operative and medical records.
Conclusion
Results of recurrent surgery to treat recurrent or persistent SUI
are still good in experienced hands and complication rates are
comparable to those of primary surgery. The treatment of
choice should always be adapted to the specific patient needs,
especially in recurrent cases. In our opinion recurrent SUI
symptoms should only be treated with utmost skill and only
by trained and experienced surgeons, preferably in a tertiary
referral center. Patients should be informed about the potential
risks of recurrent SUI surgery, in particular about exposure
and voiding difficulties. Our results support the claims of the
contemporary literature that retropubic midurethral slings are
the first choice in the treatment of SUI symptoms after failure
of a previous anti-incontinence operation. Long-term follow-
up is important because of a time-dependent decline in cure
rate.
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